Summary Objectives: To evaluate the incidence of and risk factors for hypertensive disorders in a cohort of HIV-infected pregnant women. Methods: Hypertensive disorders (HD) including preeclampsia/eclampsia (PE/E) and pregnancy induced hypertension, and risk factors were evaluated in a cohort of HIV-infected pregnant (OR Z 2.1; 95% CI: 1.2e3.6) and age 35 years (OR Z 1.8; 95% CI: 1.1e3.2). PE/E was increased among women with a gBMI 25 kg/m 2 (OR Z 3.0; 95% CI: 1.5e6.0) and Hg 11 g/ dL at delivery (OR Z 2.8; 95% CI: 1.2e6.5). A previous history of PE/E increased the risk of PE/E 6.7 fold (95% CI: 1.8e25.5). HAART before conception was associated with PE/E (OR Z 2.3; 95% CI: 1.1e4.9). Conclusions: HIV-infected women, with a previous history of PE/E, a gBMI 25 kg/m 2 , Hg at delivery 11 g/dL and in use of HAART before conception are at an increased risk of developing PE/E during pregnancy.
Introduction
The prevention of maternal to child transmission (PMTCT) of HIV has progressed from recommending caesarean section, formula feeding, and treatment with Zidovudine monotherapy, 1 to additionally, implementing the use of highly active antiretroviral therapy (HAART), which led to transmission rates as low as 1e2%. 2 In spite of this impressive result, the use of HAART during pregnancy has been related to adverse outcomes such as low birth weight, prematurity, 3 and an increased rate of gestational diabetes was observed comparing data before and after the introduction of HAART. 4 Hypertensive disorders during pregnancy are a major cause of morbidity and mortality for both mother and child worldwide, and are the number one cause of maternal mortality in some regions in Brazil. 5, 6 However, prevalence data on preeclampsia and eclampsia (PE/E) among HIV-infected women are discrepant. In PACTG 185, where pregnant women were treated predominantly with ZDV during pregnancy, PE was reported to be as low as 2% among 497 women studied. 7 In the USA, the rate of PE has remained stable, regardless of the use of HAART during pregnancy. 4 Other studies have suggested that HIV-infected pregnant women treated with HAART have an increased risk for PE and fetal death. 8, 9 Wimalasundera et al. (2002) showed that the rate of PE in HIVinfected women was not different from that in uninfected pregnant women (4.2% vs. 5.6%, respectively), but within the HIV-infected women, the rate of PE in those treated with mono or dual therapy was 0e1% compared to 11% among those treated with triple therapy. 8 A probable role of immune reconstitution was implicated in the pathogenesis of PE in women treated with HAART. Suy et al. (2006) 9 found higher rates of PE among HIV-infected women (11/100 deliveries) when compared to HIV-uninfected women (2.9/100 deliveries). They also demonstrated that the rate of PE among HIV-infected women increased from 0% to 11% in two periods studied, and that this increment was related to use of HAART, especially in those treated with HAART prior to pregnancy.
In Latin America, the prevalence of PE among HIVinfected women has been rarely studied. In one report from Brazil, the rate of PE was 0.8% in HIV-infected women (1/123) and 10% among 1708 HIV-negative women, where 78% of the first group were treated with HAART. 10 As more HIV-infected women are being put on HAART earlier in pregnancy it is important to understand the impact of HAART on hypertensive disorders during pregnancy. Our objectives were to determine the prevalence of and risk factors for hypertensive disorders and PE/E among HIV-infected pregnant women in Latin America and to evaluate the impact of HAART in the development of these complications.
Methods
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) International Site Development Initiative (NISDI) and the Perinatal Longitudinal Study in Latin American Countries (LILAC) are two consecutive observational, prospective cohorts of HIVinfected pregnant women enrolled from 2002 to 2009. The main objectives of the NISDI Perinatal and LILAC Studies are to describe utilization of interventions for PMTCT of HIV, rates of mother-to-child infection, and to characterize adverse events associated with receipt of and exposure to ARVs.
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The protocols were approved by the ethics committee review board in each clinical site enrolling subjects, the sponsoring institution (NICHD), and the data management and statistical center (Westat). Clinical, immunologic, and virologic characteristics of the women were assessed at enrollment, during pregnancy, at the time of hospital discharge after delivery, and at the 6e12 week postpartum visit. Maternal history of substance use during the index pregnancy was ascertained through patient interview at enrollment. Maternal clinical disease staging 12 was performed at each study visit. Gestational age-adjusted maternal BMI (gBMI), an approach to correcting for the weight gain expected to occur during pregnancy, was calculated using a program produced by the Argentinean Ministry of Health. 13 Women who enrolled with a gBMI >25 were considered overweight.
Our study population was restricted to women enrolled in the NISDI Perinatal or LILAC protocols for the first time (second pregnancies on-study excluded), prior to labor and delivery (L&D), and whose infant were born at 20 weeks gestation. Women with pre-existing nephropathy were also excluded. HAART was defined as the use of at least three drugs in two different classes. Other non-HAART regimens (mono, dual, triple NRTI) therapy was categorized as "other ARV".
The primary outcome measure of interest was the diagnosis of any hypertensive disorder (HD) after 20 weeks of gestation. This included all cases of pregnancy induced hypertension (PIH) [defined as blood pressure persistently 140/90 mmHg without proteinuria and onset after first 20 weeks gestation with no hypertension prior to pregnancy], PE [defined as blood pressure persistently 140/90 with: proteinuria of 1þ by dipstick, on two occasions, and/or 300 mg protein in 24 h urine collection], and eclampsia [defined as seizure during pregnancy in the absence of any underlying known etiology or without any known reason for seizure and no suspicion of epilepsy or trauma]. Previous history of hypertension (not associated with pregnancy), PIH, preeclampsia or eclampsia was obtained at enrollment. Gestational age at enrollment was estimated based on the date of the last menstrual period or any earlier ultrasound dating, if available. Analyses were also done in the subset of participants who experienced PE/E.
Statistical analysis
Descriptive statistics (frequencies) were used to describe the study population. Bivariate analyses (Fisher's exact test) examined the association of hypertensive disorders (HD) and the subset of PE/E with variables assessed at the time of eligibility for the study.
All covariates with alpha level of 0.2 or lower in bivariate analyses were considered candidates for inclusion in the adjusted models. Logistic regression modeling used forward stepwise, backward elimination. All analyses were conducted using the SAS statistical software, version 9.0 (SAS Institute Inc. Cary, NC).
Results
Of 1548 women experiencing their first pregnancy on study, thirty-five were excluded; three were lost to follow-up, twenty-one enrolled at the time of L&D, six delivered at <20 weeks gestation, and five for pre-existing nephropathy, leaving 1513 women in the final study population (Fig. 1) .
The majority of women were from Brazil (62.5%). Maternal age ranged from 20 to 34 years old for 77.7% of the participants, 72.9% were married or living with a partner, 56.2% enrolled in the cohort during the third trimester of pregnancy and 86.1% reported at least one previous pregnancy prior to study enrollment (Table 1) .
There were 73 cases of HD: 38 (52.1%) diagnosed with PIH and 35 (47.9%) diagnosed with PE/E for a cumulative prevalence for HD of 4.8% (95% CI: 3.8%e6.0%) and 2.3% (95% CI: 1.7%e3.2%) for PE/E. Three women developed eclampsia, but none died. Among those diagnosed with PIH, 81.6% (31/3) had documented normal blood pressures at the time of enrollment prior to their diagnosis of hypertension.
On bivariate analyses, HD was significantly more frequent among women who were gainfully employed, married or living with a partner, gBMI 25 at enrollment, and with a higher hemoglobin value (11 g/dL) at enrollment and following delivery. While use of any antiretroviral therapy (ARV) at conception was not significantly associated with HD, being on HAART or any PI regimen at conception was associated with HD (p Z .04) ( Table 2) .
On bivariate analyses, the association of PE/E with risk factors was similar to HD; hemoglobin at delivery (11 g/ dL), gBMI 25 kg/m 2 at enrollment and a previous history of PE/E were all statistically significant factors for PE/E. We did not observe an association with employment or maternal age (Table 2) . Being on any HAART or any PI at conception or during the 1st or 2nd trimester were all associated with increased risk of PE/E.
Logistic regression models were run using all variables with p values 0.2 which included: maternal age, employment, marital status, previous history of PE/E, gBMI, trimester of enrollment, ARV at conception, type of ART at conception, ART during 1st and 2nd trimesters (different models for each time period of ART use), and hemoglobin at delivery. Additional models were run forcing CD4 and viral load (to adjust for disease severity) to remain in the model. In the final logistic regression model, HD was significantly associated with women enrolled with a gestational age-adjusted (gBMI) 25 kg/m 2 (OR Z 3.1; 95% CI: 1.9e5.0), maternal age 35 years (OR Z 1.8; 95% CI: 1.1e3.2), and Hg 11 g/dL at delivery (OR Z 2.1; 95% CI: 1.2e3.6). Similarly, PE/E was significantly increased among women enrolled with a gBMI 25 kg/m 2 (OR Z 3.0; 95% CI: 1.5e6.0) and Hg 11 g/dL at delivery (OR Z 2.8; 95% CI: 1.2e6.5). A history of PE/E in previous pregnancies was an independent risk factor increasing the risk of PE/E 6.7 times (95% CI: 1.8e25.5) compared to those without a history of PE/E (Table 3) . Being on HAART at conception was associated with a PE/E in adjusted models (OR Z 2.3; 95% CI: 1.1e4.9). Forcing CD4 and viral load (at enrollment or at the time of delivery) into the model had no impact on the final models.
Discussion
In this study of HIV-infected pregnant women, we found the prevalence of HD and PE/E was 4.8% and 2.3%, respectively. These percentages are similar to the prevalence of HD and PE/E found among pregnant women described in some Latin America countries. 14, 15 Data from the World Health Organization (WHO) Antenatal Care Trial, which included more than 39,000 pregnant women (with unknown HIV status) from Argentina, Cuba, Saudi Arabia and Thailand described PIH in 7.0% and PE/E in 2.2%.
14 In Brazil, a study with almost 5000 pregnant women with unknown HIV status, enrolled between 1991 and 1995, showed that 3.5% develop PIH and 2.3% develop PE/E. 15 In this cohort, some risk factors for PE and HD were the same described for HIV-uninfected population such as older maternal age, 16 ,17 a previous history of PE/E, 18, 19 and being overweight. 20, 21 Several abnormalities associated with the development of PE such as lower plasma volume, activation of complement system, hyperferritinemia, insulin resistance and metabolic syndrome are also more prevalent among overweight or obese uninfected patients.
22e26 Futhermore, overweight has been associated with oxidative stress consisting of an imbalance of lipid metabolism and an inflammatory state that is also associated with PE. 27 As almost 50% of the patients in this study were enrolled during the 3rd trimester of pregnancy we cannot disregard the fact that the increased weight can also be related to fluid retention. In general, reduction of weight in an overweight or obese women prior to conception has been shown to reduce PE and improve other health outcomes 28, 29 and should be also emphasized to HIV-infected women.
Higher hemoglobin among patients with PE/E and HD is expected and explained by the hemoconcentration caused by failure to increase the plasma volume during pregnancy, which is characteristic of PE. Usually, pregnant women start the expansion of plasma volume around the 7th week of gestation and this reaches a plateau around 32 weeks. 30 During pregnancy, uninfected women increase their plasma volume by almost 45% but this increase is 50% lower for those with PE/E. 31, 32 Failure to increase the plasma volume during pregnancy leads to hemoconcentration, a higher vascular resistance with a consequently decrease in uteroplacental flow and higher odds for perinatal complications. 33 The role of HIV-infection in the development of preeclampsia is controversial. Wimalasundera et al. found a lower rate of PE among untreated HIV-infected women 8 when compared to uninfected women or HIV-infected on treatment. More recently, Kalumba et al. 34 described a lower rate of HIV-infection among women with preeclampsia when compared with women without preeclampsia. Several studies show no difference in the rates of PE between HIV-uninfected and HIV-infected women treated with HAART 35, 36 or even a lower rate of PE among HIVinfected treated when compared to uninfected women. 10 We observed that the use of HAART at conception was a risk factor for PE/E. This is in agreement with two other studies which showed that the use of HAART prior to pregnancy increase the odds for hypertension and PE. 9, 37 Lack of stratification with the use of HAART in relation to pregnancy could explain the discrepancy among studies. Some authors suggest that immune restoration, secondary to the use of HAART could be involved in the development of PE. 8 It has been shown that low levels of retinol are correlated with PE and it was suggested that a mechanism of HAART-induced PE could be a reduction of serum retinol concentrations due to hepatotoxicity. 38, 39 HIV-infected pregnant women using HAART present a shift towards a Th1 cytokine production while, in a healthy pregnancy, a Th2 response is predominantly observed. 40, 41 Also a Th1 immune response is observed in PE. 42 It is possible that HIVinfected pregnant women on HAART, especially those with long exposure to therapy, would have a blunted shift of Th2 cytokines increasing the predisposition to eclampsia.
The current pathophysiological mechanism of preeclampsia involves poor placental perfusion and the excessive release of inflammatory factors that damage the mother's vascular endothelial cells, resulting in systemic hypertension and endothelial dysfunction. 43 In addition, regarding HIV-infected patients, some ART has been associated with endothelial dysfunction and CVD. 44 Nevertheless, Torriani et al. (2008) , 45 comparing three different randomized ARV regimens among HIV-infected na€ ıve individuals, in order to evaluate the effect of these ARV on endothelial function, noticed rapid improvement of endothelial function after ARV administration. Savvidou et al. (2011) evaluated the uteroplacental circulation by Doppler ultrasound of HIV-infected and non-infected pregnant women in the first trimester of gestation e a probable early biomarker to predict PE e with the aim to assess the degree of placental invasion. They found normal placental perfusion among HIV-infected women, with uncomplicated pregnancies, receiving and not receiving ARV regimen. Although, these authors state that the majority of women presented CD4 cell count >250 cells/mm 3 and, therefore, they could not exclude problems of uteroplacental perfusion in women with a compromised immune system. 46 Among the strengths of this study are the large size of the cohort, enrollment of study participants across several countries in Latin America and the Caribbean and the prospective collection of data with a very low rate of loss to follow-up. One of the limitations of this study is that we did not have information regarding adherence to ART and, also, we did not collect data on the duration of ART prior to the current pregnancy.
Strategies to prevent HD among HIV-infected women should include preconception counseling to high-risk women who are planning a pregnancy. It would also be interesting to compare risk of HD between women on treatment longer before pregnancy with normalization of CD4þ T-cell counts with those who started HAART during pregnancy but have already a lower CD4þ T-cell count.
The findings of this study showing a significant association of BMI 25, a history of PE/E in previous pregnancies and hemoconcentration with PE are consistent with the literature regarding risk factors for PE and HD in uninfected pregnant women. Being on HAART at conception was associated with a 2.3 times risk of developing PE/E during pregnancy.
